Itepekimab met the primary endpoint in one of two COPD phase 3 studies AERIFY-1 study met its primary endpoint of a statistically significant reduction in moderate or severe exacerbations in former ...

The FDA has granted Orphan Drug designation to NS-229 for the treatment of eosinophilic granulomatosis with polyangiitis.

Tezepelumab demonstrated clinically relevant benefits in specific inflammatory subtypes of COPD - an historically underserved market.

The planned development outside of Dallas, organized by members of a local mosque, has drawn intense scrutiny from Republicans. By J. David Goodman The Justice Department has opened an ...

Discover chronic myeloproliferative disorders—their types, causes, symptoms, diagnosis methods, and treatment options to help ...

NS-229 is currently being evaluated in a phase 2 trial in patients with eosinophilic granulomatosis ... Research & Development, Takeshi Seita. “Our therapy has been designed to target this ...

a lot of our patients have elevated eosinophils for other reasons, like allergic asthma or allergic diseases,” he said. “That might put them at higher risk for development of these ...

Conditions like asthma and allergic rhinitis can present with respiratory symptoms and blood eosinophilia. The key red flags in such cases would be the development of other multiorgan symptoms, as ...

Background and Aim Allergies have been implicated in the pathogenesis of eosinophilic gastrointestinal ... allergen is closely associated with their development. The aim of this study is to ...

--(BUSINESS WIRE)--Holoclara, a biotechnology company pioneering the development of worm-derived therapies for allergic and autoimmune disorders, today announced the selection of eosinophilic ...

17 May 2024 Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the ...